Bo Zhang

46PUBLICATIONS
40CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSolid tumoursCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (46)

|Jun 15, 2026
Efficacy and safety of first-line oral vinorelbine plus firmonertinib in refractory <i>EGFR</i>-mutated non-small cell lung cancer: study protocol of a multicenter, non-randomized, two-cohort study.

|May 25, 2026
Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis.

|May 07, 2026
GLUT6-facilitated noncanonical glucose metabolic rewiring enables resistance to targeted cancer therapy.

|Aug 30, 2025
WEE1 inhibitor exerts synergistic effect with KRAS G12C inhibitor via MYBL2-RRM2 axis in KRAS<sup>G12C</sup>-mutant lung cancer.

Chao Zhou, Yuqing Liu, Hongyu Liu

|Jul 17, 2025
Efficacy of immunotherapy in advanced <i>ALK</i>-rearranged non-small cell lung cancer patients with disease progression on ALK-TKIs.

Danni Wang, Yujing Li, Beibei Liu

|May 02, 2025
Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancer.

Hongyu Liu, Chao Zhou, Jun Lu

Pageof 8

Frequent Collaborators

8 joint publications

Runbo Zhong

5 joint publications

Jun Lu

4 joint publications

Kai Li

3 joint publications

Liang Zhu